Cargando…

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid

Adjuvant endocrine therapy (AET) is the treatment of choice for early-stage estrogen receptor alpha (ERα)-positive breast cancer (BC). However, almost 40% of tamoxifen-treated cases display no response or a partial response to AET, thus increasing the need for new treatment options and strong predic...

Descripción completa

Detalles Bibliográficos
Autores principales: Meligova, Aggeliki K., Siakouli, Dimitra, Stasinopoulou, Sotiria, Xenopoulou, Despoina S., Zoumpouli, Maria, Ganou, Vassiliki, Gkotsi, Eleni-Fani, Chatziioannou, Aristotelis, Papadodima, Olga, Pilalis, Eleftherios, Alexis, Michael N., Mitsiou, Dimitra J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959521/
https://www.ncbi.nlm.nih.gov/pubmed/36835157
http://dx.doi.org/10.3390/ijms24043747
_version_ 1784895297534558208
author Meligova, Aggeliki K.
Siakouli, Dimitra
Stasinopoulou, Sotiria
Xenopoulou, Despoina S.
Zoumpouli, Maria
Ganou, Vassiliki
Gkotsi, Eleni-Fani
Chatziioannou, Aristotelis
Papadodima, Olga
Pilalis, Eleftherios
Alexis, Michael N.
Mitsiou, Dimitra J.
author_facet Meligova, Aggeliki K.
Siakouli, Dimitra
Stasinopoulou, Sotiria
Xenopoulou, Despoina S.
Zoumpouli, Maria
Ganou, Vassiliki
Gkotsi, Eleni-Fani
Chatziioannou, Aristotelis
Papadodima, Olga
Pilalis, Eleftherios
Alexis, Michael N.
Mitsiou, Dimitra J.
author_sort Meligova, Aggeliki K.
collection PubMed
description Adjuvant endocrine therapy (AET) is the treatment of choice for early-stage estrogen receptor alpha (ERα)-positive breast cancer (BC). However, almost 40% of tamoxifen-treated cases display no response or a partial response to AET, thus increasing the need for new treatment options and strong predictors of the therapeutic response of patients at high risk of relapse. In addition to ERα, BC research has focused on ERβ1 and ERβ2 (isoforms of ERβ), the second ER isotype. At present, the impact of ERβ isoforms on ERα-positive BC prognosis and treatment remains elusive. In the present study, we established clones of MCF7 cells constitutively expressing human ERβ1 or ERβ2 and investigated their role in the response of MCF7 cells to antiestrogens [4-hydroxytamoxifen (OHΤ) and fulvestrant (ICI182,780)] and retinoids [all-trans retinoic acid (ATRA)]. We show that, compared to MCF7 cells, MCF7-ERβ1 and MCF7-ERβ2 cells were sensitized and desensitized, respectively, to the antiproliferative effect of the antiestrogens, ATRA and their combination and to the cytocidal effect of the combination of OHT and ATRA. Analysis of the global transcriptional changes upon OHT–ATRA combinatorial treatment revealed uniquely regulated genes associated with anticancer effects in MCF7-ERβ1 cells and cancer-promoting effects in MCF7-ERβ2 cells. Our data are favorable to ERβ1 being a marker of responsiveness and ERβ2 being a marker of resistance of MCF7 cells to antiestrogens alone and in combination with ATRA.
format Online
Article
Text
id pubmed-9959521
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99595212023-02-26 ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid Meligova, Aggeliki K. Siakouli, Dimitra Stasinopoulou, Sotiria Xenopoulou, Despoina S. Zoumpouli, Maria Ganou, Vassiliki Gkotsi, Eleni-Fani Chatziioannou, Aristotelis Papadodima, Olga Pilalis, Eleftherios Alexis, Michael N. Mitsiou, Dimitra J. Int J Mol Sci Article Adjuvant endocrine therapy (AET) is the treatment of choice for early-stage estrogen receptor alpha (ERα)-positive breast cancer (BC). However, almost 40% of tamoxifen-treated cases display no response or a partial response to AET, thus increasing the need for new treatment options and strong predictors of the therapeutic response of patients at high risk of relapse. In addition to ERα, BC research has focused on ERβ1 and ERβ2 (isoforms of ERβ), the second ER isotype. At present, the impact of ERβ isoforms on ERα-positive BC prognosis and treatment remains elusive. In the present study, we established clones of MCF7 cells constitutively expressing human ERβ1 or ERβ2 and investigated their role in the response of MCF7 cells to antiestrogens [4-hydroxytamoxifen (OHΤ) and fulvestrant (ICI182,780)] and retinoids [all-trans retinoic acid (ATRA)]. We show that, compared to MCF7 cells, MCF7-ERβ1 and MCF7-ERβ2 cells were sensitized and desensitized, respectively, to the antiproliferative effect of the antiestrogens, ATRA and their combination and to the cytocidal effect of the combination of OHT and ATRA. Analysis of the global transcriptional changes upon OHT–ATRA combinatorial treatment revealed uniquely regulated genes associated with anticancer effects in MCF7-ERβ1 cells and cancer-promoting effects in MCF7-ERβ2 cells. Our data are favorable to ERβ1 being a marker of responsiveness and ERβ2 being a marker of resistance of MCF7 cells to antiestrogens alone and in combination with ATRA. MDPI 2023-02-13 /pmc/articles/PMC9959521/ /pubmed/36835157 http://dx.doi.org/10.3390/ijms24043747 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Meligova, Aggeliki K.
Siakouli, Dimitra
Stasinopoulou, Sotiria
Xenopoulou, Despoina S.
Zoumpouli, Maria
Ganou, Vassiliki
Gkotsi, Eleni-Fani
Chatziioannou, Aristotelis
Papadodima, Olga
Pilalis, Eleftherios
Alexis, Michael N.
Mitsiou, Dimitra J.
ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
title ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
title_full ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
title_fullStr ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
title_full_unstemmed ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
title_short ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
title_sort erβ1 sensitizes and erβ2 desensitizes erα-positive breast cancer cells to the inhibitory effects of tamoxifen, fulvestrant and their combination with all-trans retinoic acid
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959521/
https://www.ncbi.nlm.nih.gov/pubmed/36835157
http://dx.doi.org/10.3390/ijms24043747
work_keys_str_mv AT meligovaaggelikik erb1sensitizesanderb2desensitizeserapositivebreastcancercellstotheinhibitoryeffectsoftamoxifenfulvestrantandtheircombinationwithalltransretinoicacid
AT siakoulidimitra erb1sensitizesanderb2desensitizeserapositivebreastcancercellstotheinhibitoryeffectsoftamoxifenfulvestrantandtheircombinationwithalltransretinoicacid
AT stasinopoulousotiria erb1sensitizesanderb2desensitizeserapositivebreastcancercellstotheinhibitoryeffectsoftamoxifenfulvestrantandtheircombinationwithalltransretinoicacid
AT xenopouloudespoinas erb1sensitizesanderb2desensitizeserapositivebreastcancercellstotheinhibitoryeffectsoftamoxifenfulvestrantandtheircombinationwithalltransretinoicacid
AT zoumpoulimaria erb1sensitizesanderb2desensitizeserapositivebreastcancercellstotheinhibitoryeffectsoftamoxifenfulvestrantandtheircombinationwithalltransretinoicacid
AT ganouvassiliki erb1sensitizesanderb2desensitizeserapositivebreastcancercellstotheinhibitoryeffectsoftamoxifenfulvestrantandtheircombinationwithalltransretinoicacid
AT gkotsielenifani erb1sensitizesanderb2desensitizeserapositivebreastcancercellstotheinhibitoryeffectsoftamoxifenfulvestrantandtheircombinationwithalltransretinoicacid
AT chatziioannouaristotelis erb1sensitizesanderb2desensitizeserapositivebreastcancercellstotheinhibitoryeffectsoftamoxifenfulvestrantandtheircombinationwithalltransretinoicacid
AT papadodimaolga erb1sensitizesanderb2desensitizeserapositivebreastcancercellstotheinhibitoryeffectsoftamoxifenfulvestrantandtheircombinationwithalltransretinoicacid
AT pilaliseleftherios erb1sensitizesanderb2desensitizeserapositivebreastcancercellstotheinhibitoryeffectsoftamoxifenfulvestrantandtheircombinationwithalltransretinoicacid
AT alexismichaeln erb1sensitizesanderb2desensitizeserapositivebreastcancercellstotheinhibitoryeffectsoftamoxifenfulvestrantandtheircombinationwithalltransretinoicacid
AT mitsioudimitraj erb1sensitizesanderb2desensitizeserapositivebreastcancercellstotheinhibitoryeffectsoftamoxifenfulvestrantandtheircombinationwithalltransretinoicacid